AccuStem Sciences, Inc. Announces Chairman Purchase of Shares
AccuStem Sciences (OTCQB: ACUT), a clinical stage diagnostics company focused on cancer patient outcomes, has announced that Chairman of the Board Gabriele Cerrone has increased his stake in the company.
Rhea-AI Summary
Positive
- Chairman's increased stake shows confidence in company's future
- Significant total holding of 6.5 million shares by Chairman indicates strong insider commitment
Negative
- None.
Details
News Market Reaction – ACUT
The recorded move for ACUT in the trading session of this news was +26.06%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
LONDON, June 13, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced that its Chairman of the Board, Mr. Gabriele Cerrone, has notified the Company that he has recently purchased an additional 8,991 ACUT shares in the open market. This brings his total holding to 6,500,000 shares.
About AccuStem
AccuStem is a clinical stage diagnostics company dedicated to optimizing outcomes and quality of life for all patients with cancer. We plan to drive innovation in healthcare by offering proprietary molecular testing that addresses unmet clinical needs from cancer screening through treatment and monitoring. By interrogating novel disease pathways, such as tumor “stemness,” we believe our tools will help care teams better understand the biology of each patient’s cancer, leading to more informed decision making.
For more information, please visit www.accustem.com.
Investor and Media Contact:
Wendy Blosser
Email: investors@accustem.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.